In a post hoc analysis of the CANVAS trial, including patients with T2DM and normoalbuminuria, Waijer et al. [36] observed that each doubling of baseline TNFR-1 and TNFR-2 was associated with a higher risk of kidney outcome (defined as a composite of 40% reduction in eGFR, sustained eGFR < 15 mL/min/1.73 m2, need for kidney replacement therapy, and kidney-related death), with HRs of 4.2 (95% CI: 1.8–9.6) and 2.3 (95% CI: 1.5–3.6), respectively. This evidence concerns the gene TNFRSF1B and type 2 diabetes mellitus.